Literature DB >> 200357

Role of radiation therapy in combination with chemotherapy in extensive oat cell cancer of the lung: a randomized study.

C Williams, M Alexander, E J Glatstein, J R Daniels.   

Abstract

After 3 months of chemotherapy with procarbazine, vincristine, cyclophosphamide, and CCNU, patients with extensive oat cell carcinoma of the lung were randomly allocated to receive 3000 rads of involved-field irradiation and further chemotherapy or to continue with chemotherapy only. In addition, all patients received 3000 rads of prophylactic whole-brain irradiation. The addition of involved-field radiation, as given in this trial, not only failed to improve survival but was unable to alter the pattern of sites of initial relapse. There were no cases of extension to the brain in 31 consecutive patients who received prophylactic whole-brain irradiation. This was in strong contrast to a preceding trial in which six cases of brain extension occurred among 19 patients who did not receive prophylactic whole-brain irradiation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 200357

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  5 in total

1.  Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial.

Authors:  R L Souhami; D M Geddes; S G Spiro; P G Harper; J S Tobias; B S Mantell; F Fearon; I Bradbury
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-02

2.  Cure rates in small cell and non-small cell carcinoma of the lung utilizing high-dose radiotherapy and chemotherapy.

Authors:  N Akbiyik; L L Alexander
Journal:  J Natl Med Assoc       Date:  1986-03       Impact factor: 1.798

3.  Long term survival after pulmonary resection for small cell carcinoma of the lung.

Authors:  U S Prasad; A R Naylor; W S Walker; D Lamb; E W Cameron; P R Walbaum
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

4.  Cyclic alternating combination chemotherapy for small cell lung cancer.

Authors:  S K Reddy; H Takita; W W Lane; R G Vincent; T Y Chen; J E Caracandas; A M Regal
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Doxorubicin, Cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer.

Authors:  J Aisner; M Whitacre; D A VanEcho; M Wesley; P H Wiernik
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.